Daewoong Pharma Market Cap ($796.92 Million)
Market Cap & Net Worth: Daewoong Pharma (069620)
Daewoong Pharma market cap. Daewoong Pharma (KO:069620) has a market capitalization of $796.92 Million (₩1.18 Trillion) as of November 3, 2026. Listed on the KO stock exchange, this Korea-based company holds position #9593 globally and #247 in its home market, demonstrating a -0.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Daewoong Pharma's stock price ₩102200.00 by its total outstanding shares 11506270 (11.51 Million). Also see Daewoong Pharma cash conversion from operations for how efficiently the company converts equity into cash flow.
Daewoong Pharma Market Cap History (2015–2026)
Daewoong Pharma market cap history from 2015 to 2026. Data shows growth from $536.76 Million to $796.92 Million (3.21% CAGR). Check today's stock price for Daewoong Pharma for real-time trading data and today's change.
Daewoong Pharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Daewoong Pharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Daewoong Pharma (069620) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Daewoong Pharma's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.04x
Daewoong Pharma's market cap is 0.04 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $536.76 Million | $839.69 Billion | $42.93 Billion | 0.00x | 0.01x |
| 2016 | $523.17 Million | $883.92 Billion | $26.97 Billion | 0.00x | 0.02x |
| 2017 | $1.26 Billion | $960.31 Billion | $31.58 Billion | 0.00x | 0.04x |
| 2018 | $1.45 Billion | $1.03 Trillion | -$15.15 Billion | 0.00x | N/A |
| 2019 | $1.06 Billion | $1.11 Trillion | $22.01 Billion | 0.00x | 0.05x |
| 2020 | $1.28 Billion | $1.06 Trillion | $12.75 Billion | 0.00x | 0.10x |
| 2021 | $1.15 Billion | $1.15 Trillion | $24.66 Billion | 0.00x | 0.05x |
| 2022 | $1.24 Billion | $1.28 Trillion | $42.24 Billion | 0.00x | 0.03x |
| 2023 | $910.76 Million | $1.38 Trillion | $121.74 Billion | 0.00x | 0.01x |
| 2024 | $985.62 Million | $1.42 Trillion | $24.73 Billion | 0.00x | 0.04x |
Competitor Companies of 069620 by Market Capitalization
Companies near Daewoong Pharma in the global market cap rankings as of November 3, 2026. Also see Daewoong Pharma assets under control for a full breakdown of the balance sheet.
Key companies related to Daewoong Pharma by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Daewoong Pharma (2015–2026)
Market capitalization of Daewoong Pharma from 2015 to today. Between 2015 and today, Daewoong Pharma's market cap moved from $536.76 Million to $ 796.92 Million, with a yearly change of 3.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩796.92 Million | -40.68% |
| 2025 | ₩1.34 Billion | +36.31% |
| 2024 | ₩985.62 Million | +8.22% |
| 2023 | ₩910.76 Million | -26.31% |
| 2022 | ₩1.24 Billion | +7.51% |
| 2021 | ₩1.15 Billion | -9.94% |
| 2020 | ₩1.28 Billion | +20.47% |
| 2019 | ₩1.06 Billion | -26.73% |
| 2018 | ₩1.45 Billion | +14.98% |
| 2017 | ₩1.26 Billion | +140.40% |
| 2016 | ₩523.17 Million | -2.53% |
| 2015 | ₩536.76 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Daewoong Pharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $796.92 Million USD |
| MoneyControl | $796.92 Million USD |
| MarketWatch | $796.92 Million USD |
| marketcap.company | $796.92 Million USD |
| Reuters | $796.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplem… Read more